Lucentis
Lucentis approved in China
January 18, 2012Sales and Marketing China, Galvus, Lucentis, Novartis, em, emerging markets
Novartis’ eye treatment Lucentis has gained approval in China, and the firm has also launched its diabetes drug Galvus in …
NICE rejects Lucentis in diabetic macular oedema
November 29, 2011Sales and Marketing Lucentis, NICE
NICE has rejected Novartis’ Lucentis for diabetic macular oedema. NICE has not recommended Lucentis (ranibizumab) for the treatment of diabetic …
Lucentis not backed by NICE for new licence
November 24, 2011Sales and Marketing Lucentis, NICE, Novartis, Ozurdex
NICE has not recommended Novartis’ eye disease drug Lucentis due to ‘gaps and uncertainties’ in the manufacturer’s submission. In draft …
Lucentis rival gains US approval
November 22, 2011Research and Development, Sales and Marketing Bayer, Eylea, Lucentis, Novartis, Regeneron, Roche
A rival to Roche and Novartis’ drug Lucentis has received FDA approval for a common form of eye disease. Eylea …
Novartis cuts Lucentis price amid growing pressure
October 7, 2011Sales and Marketing Lucentis, wet AMD
Novartis has been forced to cut the Swiss price of its eye drug Lucentis by 30% after sharp negotiations with …
NICE to review Lucentis decision
August 17, 2011Sales and Marketing Lucentis, NICE, diabetic macular edema
NICE will allow an appeal against its decision not to recommend Novartis’s Lucentis for diabetic macular oedema. The appeal came …
NICE decides laser treatment better than Lucentis
July 18, 2011Sales and Marketing Lucentis, NICE, Novartis
Novartis says it is “disappointed” with health watchdog NICE’s decision not to recommend Lucentis for the treatment of eye problems …
Bayer submits Lucentis rival for European approval
June 7, 2011Sales and Marketing Bayer, Lucentis, Regeneron, VEGF Trap-Eye
Bayer Healthcare has submitted its new eye drug to European regulators for approval to treat age-related macular degeneration (wet AMD). …
Novartis eye drug wins wider European licence
June 6, 2011Sales and Marketing Lucentis, Novartis
Novartis’ Lucentis has been approved in Europe to treat people suffering from vision loss due to macular oedema secondary to …
Government wrong to push for Avastin in eye disease, says charity
May 12, 2011Research and Development, Sales and Marketing Lucentis, RNIB, avastin, wet AMD
The UK government’s pursuit of Avastin for use in ophthalmology is bad for patients, says the Royal National Institute of …
Avastin as effective as Lucentis in eye disease
May 4, 2011Research and Development Lucentis, avastin, off label, wet AMD
Roche’s cancer drug Avastin is as effective at treating wet AMD as Novartis’ Lucentis, which is licensed for the eye …
Bayer drug enters phase III for diabetic macular oedema
April 11, 2011Sales and Marketing Bayer, Lucentis, ophthalmology
Bayer and partner Regeneron have begun late stage trials for their VEGF Trap Eye candidate for diabetic macular oedema. The …
NICE rejects Lucentis for diabetic oedema
March 4, 2011Sales and Marketing Lucentis, NICE, Novartis, VEGF, Vascular Endothelial Growth Factor, diabetic oedema, raibizumab
NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …
Novartis becomes global eye health leader as Alcon deal finalised
December 15, 2010Manufacturing and Production, Research and Development, Sales and Marketing Alcon, Lucentis, Novartis, eye care, eye health, ophthalmology
Novartis’ 11-month standoff with Alcon shareholders has ended, allowing it to acquire all the remaining shares in the ophthalmology firm. …
Bayer’s challenger to Lucentis shows promise
November 22, 2010Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD
Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
